Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of acquired HER2/neu overexpression on circulating tumor cells in metastatic breast cancer
2008-000341-64Phase 2Completed
- Sponsor
- European Institute of Oncology
- Start
- Jul 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab in breast cancer, sponsored by European Institute of Oncology. Primary endpoint: Prevalence of concordant HER2/neu expression. Started Jul 2008; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-000341-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000341-64.